164 results about "Mental illness" patented technology

Disclosed herein is a method for treating depression associated with alcoholism in a patient comprising administering to the patient a pharmacologically effective dose of an opioid antagonist, and a pharmacologically effective dose of at least one drug compound selected from the group consisting of a tricyclic antidepressant, an a-typical antidepressant, and lithium.

A neurological control system for modulating activity of any component or structure comprising the entirety or portion of the nervous system, or any structure interfaced thereto, generally referred to herein as a “nervous system component.” The neurological control system generates neural modulation signals delivered to a nervous system component through one or more neuromodulators, comprising intracranial (IC) stimulating electrodes and other actuators, in accordance with treatment parameters. Such treatment parameters may be derived from a neural response to previously delivered neural modulation signals sensed by one or more sensors, each configured to sense a particular characteristic indicative of a neurological or psychiatric condition.

A system for and method of remote monitoring, screening, assessment and treatment of patients having a mental health illness such as post-traumatic stress disorders or other traumatic stress injury and co-occurring symptomatology. Patients in constant communication with one or more healthcare professionals through a wireless network, complete executable programs on their patient handheld electronic devices and transmit the results of the executable programs to their supervising mental health professional. The mental health professionals review and analyze the collected patient data to make clinical assessments of the patients' mental health status.

The present invention provides methods and systems or apparatuses, to analyze multiple molecular and clinical variables from an individual diagnosed with a psychiatric disorder, such as post-traumatic stress disorder (PTSD), in order to optimize medication selection for therapeutic response. Molecular co-variables include polymorphisms in genes including those involved in central control and mediation of the hypothalamic-pituitary axis (HPA) stress response, the density of methylation in regulatory regions of said polymorphic genes, polymorphisms in genes that encode cytochrome P450 enzymes responsible for drug metabolism, and drug-drug and drug-gene interactions. Clinical co-variables include but are not limited to the sex, age and ethnicity of that individual, medication history, family history, diagnostic codes, Pittsburgh insomnia rating score, and Charlson index score. The system makes a determination based on unstructured and structured data types derived from internal and external knowledge resources to determine psychotropic drug choice that best matches the molecular and clinical variation profile of an individual patient. The decision support system provides a therapeutic recommendation for a clinician based on the patient's variation profile.

The invention provides a man-machine motion interaction system and method based on expression recognition. The system comprises an image acquisition module, an image processing module, an expression recognition module, a man-machine interaction module and a storage module. The image acquisition module acquires a facial image; the image processing module processes the acquired facial image for graying, size adjustment and the like; an expression in the facial image is recognized by means of expression recognition; the man-machine interaction module feeds back to a user according to the facial expression; the statistical and storage module analyzes mental state of the user at this moment and records the mental state; meanwhile, a statistical query function is provided for the user. After applied to intelligent equipment, the system is capable of providing specific humanized responses so that the equipment can be more intelligent; when applied to mental care robots, the system is capable of capturing patients' expressions to allow for simple and effective communication with patients, so that the patients with mental illnesses can be supervised safely in real time, and effective data basis for treatment is provided for doctors.

The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:which relates to morphinan compounds useful as μ, δ, and / or κ receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.

A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and / or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes.

The present invention relates to methods of treating of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperaesthesia-dissociative phenomena- . . . ) using compounds and compositions of compounds having D4 and / or 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for. The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and / or (ii) compounds having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and / or (iii) any known medicinal compound and compositions of said compounds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biological compound or in two different chemical and / or biological compounds.

Disclosed are methods and systems for treatment planning for deep brain or superficial neuromodulation using ultrasound and other treatment modalities impacting one or multiple points in a neural circuit to produce acute effects or Long-Term Potentiation (LTP) or Long-Term Depression (LTD) to treat indications such as neurologic and psychiatric conditions. Ultrasound transducers or other energy sources are positioned and the anticipated effects on up-regulation and / or down-regulation of their direction of energy emission, intensity, frequency, firing / timing pattern, and phase / intensity relationships mapped onto the recommended treatment-planning targets. The maps of treatment-planning targets onto which the mapping occurs can be atlas (e.g., Tailarach Atlas) based or image (e.g., fMRI or PET) based. Atlas and imaged-based maps may be representative and applied directly or scaled for the patient or may be specific to the patient.

The present invention provides smell tests (odor identification tests) that are shorter that UPSIT, yet has a statistical sensitivity and specificity equivalent to or better than UPSIT. The odor identification tests of the invention are based on a core set of six odorants, where the six odorants can be selected from the following group of odorants: menthol, clove, leather, strawberry, lilac, pineapple, smoke, soap, natural gas and lemon. The present invention provides odor identification tests that can: (1) discriminate between subjects who are normal and who have a neuropsychiatric condition, cognitive disease or disorder, and / or (2) predict which subjects with mild cognitive disorders will develop various neuropsychiatric conditions or cognitive diseases and disorders. In one embodiment, the test and methods of the invention can provide an early prediction or diagnosis of Alzheimer's disease that is important for patients (including patients who have mild cognitive disorders, such as MCI) and clinicians to make plans for the future and to institute early treatment.

The present invention is a method and system for detecting linguistic markers as signs and indicators of mental illness, even prior to onset of symptoms of the mental illness. The linguistic markers may be detected in diachronic analyses of writing or speech samples. In particular, the present invention may identify lexical and syntactic changes in language due to mental illness. To recognize such changes the present invention may utilize complete, fully parsed texts or speech representing a number of measures. The identification of markers may provide a means of detecting mental illness early on based on a person's use of language. The language may be presented as spontaneous speech or writing, and may include samples of speech and / or writing occurring over time.

A diagnosis system and method comprising a handwriting data collection and analysis software and accompanying tools for diagnosing a given condition such as an illness, a mental illness, a physiological condition, a mental or emotional state, medication effect, a personality trait, a skill, an expertise, deception or truth writing. The handwriting of a control group known to have a condition is analyzed in order to determine the detectable characteristic indicators of that group. Such measured indicators comprise spatial, temporal and pressure measures for each writing stroke. The handwriting of a subject is then analyzed to determine if the measured indicators indicate statistically that the subject can be diagnosed with a condition.

Systems and methods for identifying genetic variations in a disease and diagnosing a patient with a mental illness, or a generic variant of same. The systems and methods use genomics and phenomics in a computer-implemented methods to identify biclusters in phenomic and genomic data, discover relationships among the biclusters, organize the relations into partitions, rank the predictive utility of features, and map the disease risk function. This can in turn be used to diagnose a patient in a person-centered fashion.

Disclosed are methods, systems, and devices for generating sleep predicators to avoid preventable mental episodes from breaking through, thereby averting an irreversible brain damage to a patient, that may be caused by such future mental episodes. In one embodiment, the present invention is a method comprising: acquiring biomedical data from a patient by using a means of signal acquisition; forming a database of the biomedical records in which the database further comprises a sleep prediction algorithm, psychiatric records, and a statistical engine to compute the data and the psychiatric records using the algorithm; mapping the acquired data in reference to the sleep prediction algorithm; validating the sleep predictors; and providing an output of the sleep predicators to a patient or caretaker. The present invention can be used to treat mania, depression, bipolar disorder, schizophrenia, PTSD, anxiety, and other chronic mental health conditions.

The invention discloses an emotion record, analysis and guidance system and an implementation method of the emotion record, analysis and guidance system. The emotion record, analysis and guidance system and the implementation method mainly solve the problems that an emotion guidance system with the function of preventing and reducing mental illness p in advance is not available in the prior art, and the requirement of people cannot be met. The implementation method includes the steps that an emotion management platform reads mood data of users and physiological data of the users collected by an emotion smart watch; the mood data of the users and the physiological data of the users are transmitted to a data processing center; the data processing center analyzes user information to acquire current emotion conditions of the users and stores the analysis result; when it shows that the users are in bad moods currently through analysis, the analysis result is fed back to the emotion management platform, and the emotion management platform automatically extracts funny pictures and / or jokes from a database and then sends the funny pictures and / or the jokes to user terminals. By the adoption of the scheme, the goal of preventing and reducing mental illness in advance is achieved, and the system has high practical value and promotional value.

Mental illness is a huge burden on those afflicted with it, as well as their caregivers and represents a major cost to society as a whole. The invention herein is concerned with methods and apparatus to improve the well-being of persons afflicted with mental illness, as well as to provide early and better diagnosis. It is felt that in some cases such diagnosis can lead to a potential for eliminating the worst effects of the illness altogether, by allowing intervention before a first psychotic episode occurs. The invention uses sensors, primarily 2D or 3D cameras and voice recognition to observe persons in many instances during ordinary activity such as playing video games, chatting on the internet or other such computer based activity.

Disclosed herein is a novel apparatus and the uses thereof in the prophylaxis and / or treatment of neuropsychiatric disorders. The present apparatus comprises a detecting means, a stimulation means, a virtual reality means and a processor. According to some embodiments of the present disclosure, the present apparatus produces an additive or synergistic effect on the treatment of neuropsychiatric disorders.

Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.

The present invention is a system and method of related healthcare processes protecting workplace productivity and mental health. It provides tools to patients and their physicians to assist them in identifying, managing and tracking mental health disorders. It also provides information to employers and health and disability insurers regarding the most effective interventions promoting productivity and mental and physical health. Through an interactive process with a website, the patient undergoes an initial screening for the presence of a mental health disorder, in an anonymous and confidential manner. After the first stage of screening, if the possibility of a mental disorder is identified, questions will be posed to the patient to determine the level of risk for possible diagnosis of a mental disorder by the M.D. A printable diagnostic risk map is provided in addition to appropriate care maps and follow up maps that guide physician and patient management of these disorders. Compliance with current best practices in disease management by both patient and physician is supported by scientific information at the lay level and physician level. Clinical and functional outcomes are quantified economically. Outcomes are tracked individually, but only aggregate information is provided to the employer and / or insurer. The overall result is improved mental health, physical health, productivity for large populations in a cost effective manner without requiring changes to the existing health care systems

This invention relates to compounds of formula Itheir use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and / or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

Provided is a strain CCFM8630 of Bifidobacterium adolescentis and use thereof. The strain CCFM8630 of Bifidobacterium adolescentis can significantly increase neurotransmitter 5-hydroxytryptamine level in peripheral blood of rat, recover the hormone levels, for example testosterone and so on in peripheral blood of rat, normalize abnormal abundances of Bifidobacterium genus, Blautia genus and Turicibacter genus in intestinal flora of rat affected by high-fat high-starch diet, show pretty good tolerance to simulated gastrointestinal fluid and quickly colonize in intestinal, significantly improve pathological damages of tissues such as liver, duodenum and so on, and increase triglyceride and total cholesterol levels in serum and oral glucose tolerance of rat with metabolic syndrome caused by high-fat high-starch diet. The strain CCFM8630 of Bifidobacterium adolescentis can be used for preventing, relieving or treating metabolic disorder, such as metabolic syndrome, irritable bowel syndrome and mental diseases related to metabolic syndrome such as anxiety, depression and so on.

This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease.

The invention discloses a pure Chinese medicinal preparation for treating mental illness, which is prepared from Chinese angelica, szechuan lovage rhizome, peach seed, Chinese thorowax root, radix curcumae, beautiful sweetgum fruit, fructus citri immaturus exsiccatus, dwarf lilyturf tuber, costustoot, nutgrass galingale rhizome, wrinkled gianthyssop herb, flos chrysanthemi, dried orange peel, pinellia tuber, cortex magnoliae officinalis, areca seed, oriental waterplantain rhizome, liquorice root, Chinese ligusticum rhizome and semen trichosanthis in a certain weight ratio. The medicament of the invention can be prepared into any common oral administration formulation. In a prescription of the invention, the medicaments have the excellent synergistic effect on the curative effect through reasonable compatibility; channels and collaterals are dredged through liver rejuvenation, vigoration of blood circulation, promotion of qi circulation, xeransis, phlegm elimination and melancholy dispelling, and the circulation of qi and blood all over the bodies of patients is regulated, so that the qi, blood and body fluid are evacuated normally, and viscus organs are promoted to perform normal physiological activity; and therefore, the viscus function operates normally and diseases are cured. Compared with the prior art, the pure Chinese medicinal preparation has the advantages of quick response, high cure rate, relapse prevention, no toxic or side effect and easy acceptance by the patients.

The present application relates to the use of SNPs and differential exon expression to characterize, diagnose or treat bipolar disorder and other mental illnesses, such as major depressive disorder and schizophrenia.

The invention relates to a psychological testing treatment system based on virtual reality. The psychological testing treatment system comprises a reality testing system, a VR testing treatment systemand a background server system. The reality testing system is internally provided with a VR positioning unit. The reality testing system further comprises VR helmet type glasses and a VR handle. TheVR testing treatment system comprises a virtual scene which is arranged and a VR treatment island, wherein the VR treatment island comprises a plurality of testing treatment units. The background server system comprises an information collecting system, an information storage system and a control system. According to the system, standard, systematical and scientific detecting technology is combined with metal disease treatment, thereby establishing a virtual model which can detect and treat the metal disease, and forming a detecting and treating method so that interactive design of the patientis realized in the virtual scene, thereby realizing high pertinency in testing and treatment and satisfying the testing requirements of different patients.

The invention discloses an online triage management method and system for mental illness and belongs to the mental illness triage management field. The method comprises steps that S1, a psychiatrist and a helper register separately to log into the system; S2, the helper checks a demand option through the system prompt, and the psychiatrist who meets the needs to complete the triage is automatically searched by the system; S3, the helper and the psychiatrist corresponding to the triage perform real-time video consultation; S4, after the consultation content is archived by the system, a mental health electronic file is further generated, the information is sent to the psychologist when the helper consults again according to the file; and S5, the psychiatrist is evaluated by the helper. The method is advantaged in that problems that psychologist resources are scarce and unevenly distributed, the offline mental illness medical treatment time is conflicted, the function of a consultation platform is single, and the psychological disease consultation effect is not good due to too-high cost in the prior art are solved, reasonable allocation of the psychologist resources is achieved, easyand quick consultation is promoted, and the consultation effect is improved.

Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, childhood enuresis, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.